Trials / Completed
CompletedNCT01330290
Caregivers' and Physicians' Treatment Preference in Parkinson Patients Treated With Neupro® Requiring Caregiver Support
A Multi-site, Non-interventional, Cross-sectional Evaluation of the Caregivers' and the Physicians' Preferred Route of Administration and the Physicians' Rationale for the Choice of Neupro® in Patients With Parkinson Requiring Caregiver Support
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 148 (actual)
- Sponsor
- UCB Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study objective is to evaluate advantages and disadvantages of Neupro® versus oral anti-Parkinson medication by caregivers and physicians in idiopathic Parkinson's Disease patients requiring caregiver support in nursing home or outpatient care settings.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Neupro® | Neupro patches were prescribed by the treating physician according to the Summary of the Product Characteristics. Patients with idiopathic Parkinson's Disease (iPD) were treated for at least 1 month with a combination of Levodopa (L-DOPA) or other oral iPD medication and Neupro by the time the questionnaire was completed. |
Timeline
- Start date
- 2011-03-01
- Primary completion
- 2012-08-01
- Completion
- 2012-08-01
- First posted
- 2011-04-06
- Last updated
- 2013-12-10
- Results posted
- 2013-12-10
Locations
54 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT01330290. Inclusion in this directory is not an endorsement.